Skip to main content
. Author manuscript; available in PMC: 2009 Jul 14.
Published in final edited form as: Biochem Pharmacol. 2007 Jan 7;73(9):1499–1510. doi: 10.1016/j.bcp.2007.01.010

Fig. 8.

Fig. 8

Effects of DMTU on p53 activation in vivo during cisplatin treatment. C57BL/6 mice (male, 8–10 weeks old) were divided into three groups for experiment: control, cisplatin, and cisplatin + DMTU. The cisplatin group was treated with a single dose of cisplatin (i.p., 30 mg/kg) for 3 days. The cisplatin + DMTU group was given 100 mg/kg DMTU 30 min prior to cisplatin injection, and then DMTU was given daily post-cisplatin injection. The control group was injected with vehicle solution. At the end of experiment, renal tissues were collected for immunoblot and immunofluorescence analysis of p53. (A) Immunoblot analysis of p53 and phospho-p53. Renal cortical tissues were homogenized and extracted with 2% SDS for immunoblot analysis of p53 and phospho-p53. The blots were reprobed for β-actin to monitor comparable protein loading and transferring in each lane (not shown). (B) Immunofluorescence of p53. Renal tissues were processed for immunofluorescence as described in Section 2. Shown in the figure are representative results of four animals in each group. The results show that p53 activation during cisplatin treatment is ameliorated by DMTU.